Fig. 2
From: Identification of NOTCH4 mutation as a response biomarker for immune checkpoint inhibitor therapy
Association of NOTCH4 mutation with clinical outcomes. A Histogram showing the proportions of patients who achieved an objective response rate (ORR) in NOTCH4-WT and NOTCH4-MUT tumors. B Histogram showing the proportions of patients who achieved a durable clinical benefit (DCB) in NOTCH4-WT and NOTCH4-MUT tumors. C Predictive value of NOTCH4 mutation for progression-free survival (PFS) in the discovery cohort. D Predictive value of NOTCH4 mutation for overall survival (OS) in the discovery cohort